ARPA-H Launches Two New Programs
EMBODY: Engineering of Immune Cells Inside the Body
The goal of EMBODY is to radically alter how immune therapies are developed and delivered for life-threatening and chronic conditions by retraining healthy immune cells, and eliminating time, cost and access hurdles.
“By developing agents that target specific immune cell types, essentially providing instructions to cells already active inside your body, we hope to make advanced immunotherapies available close to home for Americans across the country,” said EMBODY Program Manager Daria Fedyukina, Ph.D., in ARPA-H’s recent program announcement.
PRINT (Personalized Regenerative Immunocompetent Nanotechnology Tissue)
PRINT intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on organs that will not require immunosuppressive drugs.
“By starting from multiple different types of cells, we will be creating organs that will be individually matched,” said PRINT Program Manager Ryan Spitler, Ph.D., in ARPA-H’s recent program announcement. “The body will not recognize it as a foreign entity, eliminating the need of immunosuppressive drugs, which has never been done in the history of organ transplantation.”
To learn more about both programs, including how to register for the upcoming Proposers’ Days, visit the EMBODY program page and PRINT program page
- A newly identified immune checkpoint protein may lead to future cancer therapies
Researchers have been searching for techniques to boost the effectiveness of CAR T cell therapy. The study, published in Science Immunology, suggests … - Advances in Immunology | Nucleic acid associated mechanisms in immunity and disease
Read the latest chapters of Advances in Immunology at ScienceDirect.com, Elsevier's leading platform of peer-reviewed scholarly literature. - Survival curve of the studying [IMAGE] | EurekAlert! Science News Releases
Journal of Clinical Immunology; Funder: Ministry of Education, Culture … /Health and medicine/Diseases and disorders/Immune disorders/Graft versus … - The oral-gut microbiome axis in inflammatory bowel disease: from inside to insight
In addition to the effects of metabolites, microbiome dysbiosis can produce abnormal immunological responses. Tim et al. showed that phagocytosis, … - Health Care Up After Bristol-Myers Earnings — Health Care Roundup – MarketWatch
Bristol also previewed promising data for its immunology drug, cendakimab, in two trials on patients with certain digestive conditions. Write …